reported that three nonsynonymous point mutations in ZIPK (T112M, D161N, and P216S), identified in cancer cells, decreased or abolished kinase activity which could abrogate the growth inhibitory roles of ZIPK and lead to in vitro cell proliferation. This evidence concerns the gene DAPK3 and cancer.